From the Infection Innovative Medicines Unit and the Discovery Sciences Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts 02451.
J Biol Chem. 2013 Sep 27;288(39):27960-71. doi: 10.1074/jbc.M113.485979. Epub 2013 Aug 2.
Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 10(1) m(-1)s(-1) for OXA-10 to 1.0 × 10(5) for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed.
阿维巴坦是一种非β-内酰胺β-内酰胺酶抑制剂,其活性谱包括 A、C 和选定的 D 类β-内酰胺酶。在这项工作中,测定了对临床重要酶 CTX-M-15、KPC-2、阴沟肠杆菌 AmpC、铜绿假单胞菌 AmpC、OXA-10 和 OXA-48 的酰化和脱酰化速率。酰化效率(k2/Ki)在酶谱中有所不同,从 OXA-10 的 1.1×10(1) m(-1)s(-1)到 CTX-M-15 的 1.0×10(5)。OXA-10 的抑制作用被证明遵循共价可逆机制,并且酰化的 OXA-10 显示出最长的脱酰化半衰期,大于 5 天。在多种酶中,通过质谱法评估酰化酶的稳定性。这些被抑制的酶形式对重排或水解稳定,除了 KPC-2。KPC-2 显示出缓慢的水解途径,涉及酰基-阿维巴坦复合物的断裂。研究了释放的降解产物的身份,并提出了 KPC-2 缓慢脱酰化的可能机制。